Nov 22, 2017 Last Updated 4:46 PM, Nov 21, 2017

Methotrexate has no steroid-sparing effect in patients with generalized myasthenia gravis

Published in News
Read 1089 times
Rate this item
(0 votes)

Myasthenia gravis (MG) is a chronic autoimmune disease characterized by fluctuating muscle weakness, which, in the majority of patients, is treated with corticosteroids. In a recently published clinical trial, 50 patients with generalized MG were randomly assigned to prednisone + methotrexate or prednisone + placebo. The amount of prednisone that…

Nature Reviews Neurology; June 2016

Full Text


Last modified on Saturday, 02 July 2016 09:45
Login to post comments

Registered area

Thanks to the support of
merck serono biogen sanofi

Conferences & Courses


May 7-10, 2018 


Workshop Sclerosi Multipla: dall'immunologia all'innovazione …

December 15-16, 2017 
Modena (Baggiovara) - UNA Hotel Modena

Scientific Program

Nature Conferences REGENERATION

November 16-18, 2017
Aula Caravella Santa Maria, San Raffaele Congress Centre, Milan, Itlay

Go to the

2nd Americas Schools of Neuroimmunology (ASNI)

October 3-6, 2017
Charlottesville (VA) - USA 

Go to the website

JNIInternational Brain Research Organization
Bringing Neuroscience to the World
JNIJournal of Neuroimmunology
Studies on all branches of neurosciences covering both research and clinical problems of neuroscientific interest.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies. To find out more about the cookies we use and how to delete them, see our Cookie Policy